Shares of Regenxbio Inc. (NASDAQ:RGNX) rose 5.9% during trading on Monday . The stock traded as high as $13.58 and last traded at $13.43, with a volume of 143,667 shares trading hands. The stock had previously closed at $12.68.

RGNX has been the topic of several recent analyst reports. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a research report on Monday. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research report on Wednesday, July 6th. Finally, Piper Jaffray Cos. reissued a “buy” rating and set a $33.00 price objective on shares of Regenxbio in a research report on Tuesday, July 5th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $26.75.

The stock’s 50-day moving average is $9.19 and its 200-day moving average is $10.91. The company’s market cap is $358.73 million.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. On average, equities analysts forecast that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Regenxbio stock. RS Investment Management Co. LLC boosted its stake in Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned approximately 2.84% of Regenxbio worth $12,393,000 as of its most recent filing with the SEC.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.